Joao O. Siffert
Affiliations: | Ceregene, Inc., San Diego, CA, United States |
Area:
parkinson's disease, neurotrophic factors, gene therapy, alzheimer's diseaseGoogle:
"Joao Siffert"Cross-listing: Neurotree - Alzheimer's Tree
Parents
Sign in to add mentor| Scott L. Pomeroy | post-doc | 1993-1994 | Harvard Medical School/Children's Hospital |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zorowitz RD, Alexander DN, Formella AE, et al. (2018) Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial. Pm & R : the Journal of Injury, Function, and Rehabilitation |
| Rafii MS, Tuszynski MH, Thomas RG, et al. (2018) Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. Jama Neurology |
| Silberstein S, Winner PK, McAllister PJ, et al. (2017) Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered(®) Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan. Headache |
| Fox SH, Metman LV, Nutt JG, et al. (2017) Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society |
| Hammond FM, Alexander DN, Cutler AJ, et al. (2016) Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. Bmc Neurology. 16: 160 |
| Hammond FM, Alexander DN, Cutler AJ, et al. (2016) PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. Bmc Neurology. 16: 89 |
| Hammond F, Alexander DN, Cutler AJ, et al. (2016) An Open-Label Study to Assess Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect (PBA) in Dementia, Stroke and Traumatic Brain Injury: PRISM II Combined Cohort Results for Patients Aged ≥65 Years American Journal of Geriatric Psychiatry. 24 |
| Doody RS, D'Amico S, Cutler AJ, et al. (2015) An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. Cns Spectrums. 1-10 |
| Cummings JL, Lyketsos CG, Peskind ER, et al. (2015) Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. Jama. 314: 1242-54 |
| Hammond F, Sauve W, Shin P, et al. (2015) Poster 62 Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect in Patients with Traumatic Brain Injury: PRISM-II Pm&R. 7 |